162 related articles for article (PubMed ID: 28570097)
1. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
[TBL] [Abstract][Full Text] [Related]
2. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
3. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
4. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Smith AD; Lieber ML; Shah SN
AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
[TBL] [Abstract][Full Text] [Related]
5. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT.
Brufau BP; Cerqueda CS; Villalba LB; Izquierdo RS; González BM; Molina CN
Radiographics; 2013 Oct; 33(6):1691-716. PubMed ID: 24108558
[TBL] [Abstract][Full Text] [Related]
6. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
[TBL] [Abstract][Full Text] [Related]
7. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
8. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
9. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
[TBL] [Abstract][Full Text] [Related]
10. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Krajewski KM; Nishino M; Ramaiya NH; Choueiri TK
AJR Am J Roentgenol; 2015 Mar; 204(3):W282-8. PubMed ID: 25714313
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy.
Han KS; Jung DC; Choi HJ; Jeong MS; Cho KS; Joung JY; Seo HK; Lee KH; Chung J
Cancer; 2010 May; 116(10):2332-42. PubMed ID: 20225226
[TBL] [Abstract][Full Text] [Related]
12. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.
Nathan PD; Vinayan A; Stott D; Juttla J; Goh V
Cancer Biol Ther; 2010 Jan; 9(1):15-9. PubMed ID: 20009542
[TBL] [Abstract][Full Text] [Related]
13. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.
Krajewski KM; Nishino M; Franchetti Y; Ramaiya NH; Van den Abbeele AD; Choueiri TK
Cancer; 2014 Mar; 120(5):711-21. PubMed ID: 24264883
[TBL] [Abstract][Full Text] [Related]
14. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
Krajewski KM; Franchetti Y; Nishino M; Fay AP; Ramaiya N; Van den Abbeele AD; Choueiri TK
Oncologist; 2014 May; 19(5):507-14. PubMed ID: 24755461
[TBL] [Abstract][Full Text] [Related]
15. Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies.
Sirous R; Henegan JC; Zhang X; Howard CM; Souza F; Smith AD
Abdom Radiol (NY); 2016 Jun; 41(6):1086-99. PubMed ID: 27193601
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical outcomes of antiangiogenic-targeted therapy in patients with pulmonary metastatic renal cell carcinoma using non-contrast-enhanced computed tomography.
Wu GY; Suo ST; Kong W; Jin D; Zhang J; Xu JR
Acad Radiol; 2014 Nov; 21(11):1434-40. PubMed ID: 25097010
[TBL] [Abstract][Full Text] [Related]
17. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.
Williams R; Hudson JM; Lloyd BA; Sureshkumar AR; Lueck G; Milot L; Atri M; Bjarnason GA; Burns PN
Radiology; 2011 Aug; 260(2):581-90. PubMed ID: 21555352
[TBL] [Abstract][Full Text] [Related]
18. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker.
Goh V; Ganeshan B; Nathan P; Juttla JK; Vinayan A; Miles KA
Radiology; 2011 Oct; 261(1):165-71. PubMed ID: 21813743
[TBL] [Abstract][Full Text] [Related]
19. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
[TBL] [Abstract][Full Text] [Related]
20. Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.
Mytsyk Y; Pasichnyk S; Dutka I; Dats I; Vorobets D; Skrzypczyk M; Uteuliyev Y; Botikova A; Gazdikova K; Kubatka P; Urdzik P; Kruzliak P
Clin Exp Med; 2020 May; 20(2):277-287. PubMed ID: 32026157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
